- Total operating performance up by 6.2 per cent
- Revenue increased
- Profit before tax above previous year’s level
The PHOENIX group is presenting stable key financial figures for the first half of 2024/25 (February to July 2024). “Our forecast of the past fiscal year has been confirmed,” says Sven Seidel, Chief Executive Officer of PHOENIX Pharma SE. “Our business model has proven itself in a volatile market environment, and we have recorded growth in revenue and earnings.” Compared with the first six months of the previous year, total operating performance increased by 6.2 per cent to €29.6 billion. This figure comprises revenue and handling for service charge. The PHOENIX group, which operates in 29 European countries, also achieved an increase in revenue of 5.2 per cent to €24.4 billion.
Earnings before interest, taxes, depreciation, and amortisation (EBITDA) rose from €411.6 million to €551.8 million. This includes a gain from the re-evaluation of a shareholding in connection with a business combination achieved in stages of €12.3 million. Adjusted for this effect and the deconsolidation loss in Switzerland in the previous year, EBITDA totalled €539.5 million, €114.5 million higher than in the comparative period.
Providing impetus for growth
“The results of the first six months show that we are on the right track in our anniversary year despite the challenging market,” explains Sven Seidel. “We are building on the achievements of the past three decades and are providing the necessary impetus for future growth also in this fiscal year.”
Increase in earnings expected
For fiscal year 2024/25, the PHOENIX group expects to expand its market position in Europe through organic growth, efficiency gains, and acquisitions and thereby increase revenue slightly above the level of growth on the European pharmaceutical markets. Revenue growth is expected in nearly all markets in which the PHOENIX group is present.
A noticeable increase in profit before tax compared with the previous year and a slight increase in the equity ratio are expected for fiscal year 2024/25.
Key figures of PHOENIX Pharma SE compared with the same period of the previous year
| 1st half of 2023/24 in €m | 1st half of 2024/25 in €m | |
| Total operating performance1 | 27,856.3 | 29,592.8 |
| Revenue | 23,209.1 | 24,404.4 |
| EBITDA (before significant one-off effects) | 425.0 | 539.5 |
| EBITDA | 411.6 | 551.8 |
| EBIT | 208.6 | 334.9 |
| Profit before tax (before significant one-off effects) | 144.3 | 248.6 |
| Profit before tax | 130.9 | 260.9 |
| Profit after tax | 86.8 | 194.5 |
| Equity*2 | 3,338.8 | 3,613.5 |
| Equity ratio (in %)*2 | 24.4 | 24.4 |
| Net debt* | 3.320.2 | 3,315.7 |
(Balance sheet date 31/07/2024)
* 31 July 2023 was restated due to the finalisation of a purchase price allocation.
1 Total operating performance = revenue + handled volume (handling for service charge).
2 As at reporting dates 31/07/2023 and 31/07/2024.
